VEGFA and cancer: Recently, for hepatocellular cancer (HCC, an aggressive cancer), an anti-VEGF agent (bevacizumab 15 mg/kg) was added to atezolizumab (an ICB) to achieve higher response rates and longer survivals [34] in the IMbrave150 Trial for unresectable HCCs.